|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
|
19470936 |
2009 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MDM2 309GG variant was at reduced risk for developing CaP (P = 0.041; OR, 0.59).
|
20822933 |
2012 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer.
|
21539745 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Although p53-inactivating mutations have been described in the majority of human cancers, their role in prostate cancer is controversial as mutations are uncommon, particularly in early lesions. p53 is activated by hypoxia and other stressors and is primarily regulated by the Mdm2 protein.
|
15550400 |
2005 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.
|
14751501 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Antisense anti-human-MDM2 mixed-backbone oligonucleotide and its mismatch control were tested in in vitro and in vivo human prostate cancer models (LNCaP, DU 145, and PC-3) for anti-tumor activity.
|
12518324 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As a novel tumor suppressor, miRNA-509-5p in prostate cancer HGC-27 cells can suppress MDM2 expression and inhibit cell proliferation, invasion, and migration.
|
28252164 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
As a result, the CCND1-RNASEL-CDKN1A-TP73-MDM2-UBE2I axis was identified as a bottleneck in the miRNA-mediated gene expression regulatory network of PCa according to network topological analysis.
|
29467540 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between polymorphisms in TP53 and MDM2 genes and susceptibility to prostate cancer.
|
28454424 |
2017 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on these results, we decided to evaluate the role of MDM2 SNP309 in the context of histopathologic parameters and clinical outcomes in prostate cancer tumors.
|
19523862 |
2011 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we demonstrate that the unrelated MDM2 antagonist Mi-63 also impinges upon AR signalling, supporting the concept of future treatment of prostate cancer with MDM2 antagonists.
|
27729622 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we evaluated the associations of prostate cancer risk and survival with the joint effects of mdm2 and p53 polymorphisms.
|
26025918 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a human prostate cancer cell lines PC3 (p53(null)), curcumin reduced MDM2 protein and mRNA in a dose- and time-dependent manner, and enhanced the expression of the tumor suppressor p21(Waf1/CIP1).
|
17332326 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, this study demonstrates that MDM2 has a role in prostate cancer growth via p53-dependent and p53-independent mechanisms and that multiple genes are involved in the process.
|
13130078 |
2003 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this large population based case-control study, we genotyped MDM2 SNP55 in 10,779 Caucasian individuals, previously genotyped for SNP309 and SNP285, including cases of colon (n = 1,524), lung (n = 1,323), breast (n = 1,709) and prostate cancer (n = 2,488) and 3,735 non-cancer controls, as well as 299 healthy African-Americans.
|
27624283 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we tested whether interruption of MDM2 function using antisense MDM2 oligonucleotide (AS) affects the apoptotic response of prostate cancer cells to AD.
|
15176048 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lastly, variants within MDM2 and CCNG1 were protective for aggressive PCa in both ethnic groups.
|
26708993 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Mechanistically, GS25 directly bound to the RING domain of MDM2, disrupted MDM2-MDMX binding and induced MDM2 protein degradation, resulting in strong inhibition of prostate cancer cell growth and metastasis, independent of p53 and androgen receptor status.
|
29762656 |
2018 |
|
Malignant neoplasm of prostate
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No statistical difference was observed in MDM2 polymorphisms and prostate cancer prognosis.
|
20664183 |
2010 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of the EGFR and MDM2 role in integrating signaling pathways critical for prostate cancer progression, we investigated whether their selective combined blockade may have a cooperative antitumor effect in prostate cancer.
|
15269162 |
2004 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that miR-340 may function as a novel tumor suppressor in PCa through the MDM2-p53 pathway by directly targeting MDM2, which may be a promising miRNA-targeted therapy for PCa.
|
26718483 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our present study provides compelling evidence that pharmacological activation of the p53 by blocking the MDM2-p53 interaction is a promising cancer therapeutic strategy and using RITA in combination with Cisplatin not only decrease the toxic effect of Cisplatin by decreasing its dose but also increasing the apoptotic effect, warrants clinical evaluation on both colon and prostate cancer.
|
31759358 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study demonstrates that small molecule MDM2 antagonists might be useful in the treatment of human prostate cancers that retain functional p53 and androgen receptor signaling.
|
17440969 |
2007 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, there was no statistical association between MDM2 SNP309 and prostate cancer risk for the allele contrast, the GG genotype, the recessive genetic model, the dominant genetic model, and prostate cancer risk in all subjects (OR = 0.96, 95% CI 0.87-1.05, P = 0.36; OR = 0.93, 95% CI 0.75-1.15, P = 0.50; OR = 1.00, 95% CI 0.87-1.15, P = 0.99; OR = 0.93, 95% CI 0.80-1.07, P = 0.30), and between MDM2 SNP309 and bladder cancer risk (the allele contrast: OR = 1.06, 95% CI 0.89-1.27, P = 0.50; the GG genotype: OR = 1.12, 95% CI 0.79-1.61, P = 0.52; the dominant genetic model: OR = 1.03, 95% CI 0.83-1.28, P = 0.78; the recessive genetic model: OR = 1.12, 95% CI 0.84-1.49, P = 0.45).
|
27015167 |
2016 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.
|
23187804 |
2012 |